Trygve HolmÃ¸y

List of Publications by Year
in descending order

95 papers	2,576 citations	172207 29 h-index	243296 44 g-index
101 all docs	101 docs citations	101 times ranked	3390 citing authors

#	Article	IF	Citations
1	Vitamin D and disease activity in multiple sclerosis before and during interferon-Î² treatment. Neurology, 2012, 79, 267-273.	1.5	113
2	Epstein-Barr Virus in Systemic Lupus Erythematosus, Rheumatoid Arthritis and Multiple Sclerosisâ€"Association and Causation. Viruses, 2012, 4, 3701-3730.	1.5	103
3	Body size and the risk of multiple sclerosis in Norway and Italy: The EnvIMS study. Multiple Sclerosis Journal, 2015, 21, 388-395.	1.4	90
4	Randomized trial of daily high-dose vitamin D ₃ in patients with RRMS receiving subcutaneous interferon Î²-1a. Neurology, 2019, 93, e1906-e1916.	1.5	88
5	Sun exposure and multiple sclerosis risk in Norway and Italy: The EnvIMS study. Multiple Sclerosis Journal, 2014, 20, 1042-1049.	1.4	80
6	25-Hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 1280-1285.	1.4	79
7	Cerebrospinal fluid CD4+T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein. Journal of NeuroVirology, 2004, 10, 278-283.	1.0	70
8	Vitamin D in the healthy and inflamed central nervous system: access and function. Journal of the Neurological Sciences, 2011, 311, 37-43.	0.3	66
9	Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination. JAMA Neurology, 2022, 79, 307.	4.5	65
10	Cerebrospinal fluid T cells from multiple sclerosis patients recognize autologous Epstein-Barr virusâ€"transformed B cells. Journal of NeuroVirology, 2004, 10, 52-56.	1.0	61
11	An Update on Vitamin D and Disease Activity in Multiple Sclerosis. CNS Drugs, 2019, 33, 1187-1199.	2.7	59
12	Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study. Multiple Sclerosis Journal, 2015, 21, 1856-1864.	1.4	58
13	Listeria monocytogenes infection associated with alemtuzumab â€" - a case for better preventive strategies. BMC Neurology, 2017, 17, 65.	0.8	58
14	Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1833-1840.	1.4	57
15	Body mass index influence interferon-beta treatment response in multiple sclerosis. Journal of Neuroimmunology, 2015, 288, 92-97.	1.1	56
16	Vitamin D status modulates the immune response to Epstein Barr virus: Synergistic effect of risk factors in multiple sclerosis. Medical Hypotheses, 2008, 70, 66-69.	0.8	55
17	B cell depletion in the treatment of multiple sclerosis. Expert Opinion on Biological Therapy, 2019, 19, 261-271.	1.4	50
18	High BMI is associated with low ALS risk. Neurology, 2019, 93, e424-e432.	1.5	48

#	Article	IF	Citations
19	Multiple sclerosis: immunopathogenesis and controversies in defining the cause. Current Opinion in Infectious Diseases, 2008, 21, 271-278.	1.3	45
20	Effect of high-dose vitamin D₃ supplementation on antibody responses against Epsteinâ€“Barr virus in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 395-402.	1.4	43
21	Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 451-457.	1.4	39
22	Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 19-22.	0.9	39
23	Stiff person syndrome associated with lower motor neuron disease and infiltration of cytotoxic T cells in the spinal cord. Clinical Neurology and Neurosurgery, 2009, 111, 708-712.	0.6	37
24	Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology, 2015, 262, 2713-2721.	1.8	36
25	Level of education and multiple sclerosis risk after adjustment for known risk factors: The EnvIMS study. Multiple Sclerosis Journal, 2016, 22, 104-111.	1.4	35
26	Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. BMC Research Notes, 2019, 12, 497.	0.6	35
27	Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. Journal of Neurology, 2021, 268, 4522-4536.	1.8	34
28	Inflammation Markers in Multiple Sclerosis: CXCL16 Reflects and May Also Predict Disease Activity. PLoS ONE, 2013, 8, e75021.	1.1	32
29	The Discovery of Oligoclonal Bands: A 50-Year Anniversary. European Neurology, 2009, 62, 311-315.	0.6	31
30	Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a. Cellular and Molecular Immunology, 2016, 13, 57-64.	4.8	31
31	Targeting NAD+ in translational research to relieve diseases and conditions of metabolic stress and ageing. Mechanisms of Ageing and Development, 2020, 186, 111208.	2.2	31
32	Season of infectious mononucleosis and risk of multiple sclerosis at different latitudes; the EnvIMS Study. Multiple Sclerosis Journal, 2014, 20, 669-674.	1.4	30
33	The immunological basis for treatment of stiff person syndrome. Journal of Neuroimmunology, 2011, 231, 55-60.	1.1	27
34	Fat-soluble vitamins as disease modulators in multiple sclerosis. Acta Neurologica Scandinavica, 2013, 127, 16-23.	1.0	26
35	Month of birth and risk of multiple sclerosis: confounding and adjustments. Annals of Clinical and Translational Neurology, 2014, 1, 141-144.	1.7	26
36	Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. Journal of Neuroimmunology, 2014, 271, 60-65.	1.1	25

#	Article	IF	Citations
37	Vitamin D sensitive EBNA-1 specific T cells in the cerebrospinal fluid of patients with multiple sclerosis. Journal of Neuroimmunology, 2011, 240-241, 87-96.	1.1	23
38	Alpha-tocopherol and MRI Outcomes in Multiple Sclerosis â€“ Association and Prediction. PLoS ONE, 2013, 8, e54417.	1.1	22
39	Intrathecal BCR transcriptome in multiple sclerosis versus other neuroinflammation: Equally diverse and compartmentalized, but more mutated, biased and overlapping with the proteome. Clinical Immunology, 2015, 160, 211-225.	1.4	22
40	High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis â€“ a randomized controlled trial. BMC Neurology, 2017, 17, 67.	0.8	22
41	Iron and copper in progressive demyelination â€“ New lessons from Skogholt's disease. Journal of Trace Elements in Medicine and Biology, 2015, 31, 183-187.	1.5	21
42	No association of tobacco use and disease activity in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e260.	3.1	21
43	Cerebrospinal fluid Tâ€„cell clones from patients with multiple sclerosis: recognition of idiotopes on monoclonal IgG secreted by autologous cerebrospinal fluid Bâ€„cells. European Journal of Immunology, 2005, 35, 1786-1794.	1.6	20
44	Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore. Acta Neurologica Scandinavica, 2012, 126, 63-69.	1.0	20
45	Vitamin D in multiple sclerosis: implications for assessment and treatment. Expert Review of Neurotherapeutics, 2012, 12, 1101-1112.	1.4	19
46	Vitamin D status and effect of interferon-Î²1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. Journal of Neuroimmunology, 2015, 280, 21-28.	1.1	19
47	Barriers and Facilitators Related to Rehabilitation Stays in Multiple Sclerosis. International Journal of MS Care, 2015, 17, 122-129.	0.4	19
48	Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis. Multiple Sclerosis International, 2015, 2015, 1-7.	0.4	18
49	Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study. Multiple Sclerosis Journal, 2017, 23, 1018-1024.	1.4	18
50	Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulsory nationwide health registers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 303-310.	1.1	18
51	Vitamin D supplementation and neurofilament light chain in multiple sclerosis. Acta Neurologica Scandinavica, 2019, 139, 172-176.	1.0	18
52	Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 256-264.	1.1	17
53	Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report. BMC Pharmacology & Toxicology, 2018, 19, 75.	1.0	17
54	Association of Body Mass Index in Adolescence and Young Adulthood and Long-term Risk of Multiple Sclerosis. Neurology, 2021, 97, e2253-e2261.	1.5	17

#	Article	IF	Citations
55	An update on cladribine for relapsing-remitting multiple sclerosis. Expert Opinion on Pharmacotherapy, 2017, 18, 1627-1635.	0.9	16
56	Î±-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients. Multiple Sclerosis Journal, 2019, 25, 987-993.	1.4	16
57	Persistence of intrathecal oligoclonal B cells and IgG in multiple sclerosis. Journal of Neuroimmunology, 2019, 333, 576966.	1.1	16
58	ALS: Cytokine profile in cerebrospinal fluid Tâ€cell clones. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2006, 7, 183-186.	2.3	15
59	Intravascular Large B-Cell Lymphoma Presenting as Cerebellar and Cerebral Infarction. Archives of Neurology, 2007, 64, 754.	4.9	14
60	Mortality trends of amyotrophic lateral sclerosis in Norway 1951â€“2014: an ageâ€“periodâ€“cohort study. Journal of Neurology, 2016, 263, 2378-2385.	1.8	14
61	Perinatal Depression and Anxiety in Women With Multiple Sclerosis. Neurology, 2021, 96, e2789-e2800.	1.5	14
62	Idiotope-specific CD4+ T cells induce apoptosis of human oligodendrocytes. Journal of Autoimmunity, 2009, 32, 125-132.	3.0	13
63	Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis. Journal of Neuroimmunology, 2018, 323, 73-77.	1.1	13
64	Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 50, 102801.	0.9	13
65	Selective intrathecal enrichment of G1m1â€positive B cells in multiple sclerosis. Annals of Clinical and Translational Neurology, 2017, 4, 756-761.	1.7	12
66	In Silico Prediction Analysis of Idiotope-Driven Tâ€“B Cell Collaboration in Multiple Sclerosis. Frontiers in Immunology, 2017, 8, 1255.	2.2	12
67	B-cell composition in the blood and cerebrospinal fluid of multiple sclerosis patients treated with dimethyl fumarate. Multiple Sclerosis and Related Disorders, 2018, 26, 90-95.	0.9	12
68	Human Cysteine Cathepsins Degrade Immunoglobulin G In Vitro in a Predictable Manner. International Journal of Molecular Sciences, 2019, 20, 4843.	1.8	12
69	Sex ratio in multiple sclerosis mortality over 65Âyears; an age-period-cohort analysis in Norway. Journal of Neurology, 2018, 265, 1295-1302.	1.8	11
70	Hereditary motor neuron disease in a large Norwegian family with a â€œH46Râ€•substitution in the superoxide dismutase 1 gene. Neuromuscular Disorders, 2012, 22, 511-521.	0.3	10
71	Experiences with using mechanical inâ€“exsufflation in amyotrophic lateral sclerosis. European Journal of Physiotherapy, 2013, 15, 201-207.	0.7	10
72	Severe multiple sclerosis reactivation after gonadotropin treatment. Multiple Sclerosis and Related Disorders, 2018, 22, 38-40.	0.9	10

#	Article	IF	Citations
73	Serum sickness following rituximab therapy in multiple sclerosis. Neurology: Clinical Practice, 2019, 9, 519-521.	0.8	10
74	Stereotyped Bâ€cell responses are linked to IgG constant region polymorphisms in multiple sclerosis. European Journal of Immunology, 2022, 52, 550-565.	1.6	10
75	Slowly Progressing Amyotrophic Lateral Sclerosis Caused by H46R SOD1 Mutation. European Neurology, 2007, 58, 57-58.	0.6	9
76	G127R: A novel SOD1 mutation associated with rapidly evolving ALS and severe pain syndrome. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 478-480.	2.3	9
77	The idiotype connection: linking infection and multiple sclerosis. Trends in Immunology, 2010, 31, 56-62.	2.9	9
78	Natural Variation of Vitamin D and Neurofilament Light Chain in Relapsing-Remitting Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 329.	1.1	9
79	CD4+ T Cells in the Blood of MS Patients Respond to Predicted Epitopes From B cell Receptors Found in Spinal Fluid. Frontiers in Immunology, 2020, 11, 598.	2.2	8
80	Genetic and Molecular Approaches to the Immunopathogenesis of Multiple Sclerosis: An Update. Current Molecular Medicine, 2009, 9, 591-611.	0.6	7
81	Can vitamin D reduce inflammation in relapsing-remitting multiple sclerosis?. Expert Review of Neurotherapeutics, 2016, 16, 233-235.	1.4	6
82	Ethical challenges in tracheostomy-assisted ventilation in amyotrophic lateral sclerosis. Journal of Neurology, 2018, 265, 2730-2736.	1.8	6
83	Extensive Multiple Sclerosis Reactivation after Switching from Fingolimod to Rituximab. Case Reports in Neurological Medicine, 2018, 2018, 1-3.	0.3	6
84	Infectious causes of multiple sclerosis. Lancet Neurology, The, 2005, 4, 268.	4.9	5
85	A Norse Contribution to the History of Neurological Diseases. European Neurology, 2006, 55, 57-58.	0.6	5
86	Pasienttilfredshet ved rehabilitering av pasienter med multippel sklerose. Tidsskrift for Den Norske Laegeforening, 2012, 132, 523-525.	0.2	5
87	Severe inflammatory disease activity 14Âmonths after cessation of Natalizumab in a patient with Leberâ€™s optic neuropathy and multiple sclerosis â€“ a case report. BMC Neurology, 2016, 16, 197.	0.8	4
88	Strong tuberculin response after BCG vaccination is associated with low multiple sclerosis risk: a population-based cohort study. International Journal of Epidemiology, 2022, 51, 1637-1644.	0.9	4
89	Association of adverse childhood experiences with the development of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 645-650.	0.9	4
90	Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 481-488.	1.1	3

#	Article	IF	Citations
91	WT1 and interferon-Î²-vitamin D association in MS: a longitudinal study. Acta Neurologica Scandinavica, 2016, 133, 309-312.	1.0	2
92	G1m1 predominance of intrathecal virusâ€specific antibodies in multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1303-1309.	1.7	2
93	Reply to comment: Month of birth and risk of multiple sclerosis: confounding and adjustments. Annals of Clinical and Translational Neurology, 2014, 1, 376-377.	1.7	1
94	Skogholtâ€™s diseaseâ€”A tauopathy precipitated by iron and copper?. Journal of Trace Elements in Medicine and Biology, 2022, 70, 126915.	1.5	1
95	Three Elling Solheim Poems. Academic Medicine, 2006, 81, 474.	0.8	0